2018 has been an exciting year for imaging in urology, especially in the field of prostate cancer. In this context, multiparametric MRI and molecular imaging targeting prostate-specific membrane antigen provide practice-changing developments for detection and diagnostic work-up.
Key advances
-
Targeting biopsies in patients with abnormal findings on multiparamentric MRI (mpMRI) is superior to standard ultrasonography-guided biopsy in detecting clinically significant prostate cancer at initial evaluation1.
-
A minority of patients with negative mpMRI develop clinically significant prostate cancer at 4 years. Increasing PSA levels and higher PSA density predict increased likelihood of disease development3.
-
In biochemically recurrent prostate cancer, detection rates by 68Ga-PSMA-PET are ~55% and ~70% for patients with PSA values between 0.2 and 0.5 ng/ml and between 0.5 and 1.0 ng/ml, respectively5.
-
Results from 68Ga-PSMA-PET change management in approximately half of patients with biochemically recurrent prostate cancer6.
-
Novel fluorinated PSMA ligands might replace 68Ga-based PSMA ligands for PET staging of prostate cancer owing to reduced urinary excretion and advantageous pelvic imaging, easier handling and increased availability8.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).
Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).
Panebianco, V. et al. Negative multiparametric magnetic resonance imaging for prostate cancer: what’s next? Eur. Urol. 74, 48–54 (2018).
Maurer, T. et al. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 13, 226–235 (2016).
Rauscher, I. et al. Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. Eur. Urol. 73, 656–661(2018).
Han, S. et al. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur. Urol. 74, 179–190 (2018).
Maurer, T. et al. 99mTechnetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur. Urol. https://doi.org/10.1016/j.eururo.2018.03.013 (2018).
Giesel, F. L. et al. Detection efficacy of [18F]PSMA-1007 PET/CT in 251 patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. https://doi.org/10.2967/jnumed.118.212233 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
All authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Maurer, T., Eiber, M. Practice changing for prostate cancer: a vision of the future. Nat Rev Urol 16, 71–72 (2019). https://doi.org/10.1038/s41585-018-0134-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0134-6